Navigation Links
RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development

CARY, N.C., Aug. 17 /PRNewswire/ -- Exceptionally high costs.  Long research and development cycles.  Low success of clinical trials.  Slow and unpredictable regulatory reviews.  Dependence on out-dated information technology options.  It's not just time and money; there is also too much valuable information being wasted.  

Such justifiable criticisms of today's $800 billion drug development industry have led to the formation of a new company, RedOak Logic LLC, headquartered in Cary, North Carolina.  

RedOak Logic is developing an advanced decision modeling support platform and proprietary application interface -- an "Experience Management" solution -- tailored to the needs of the global drug development industry.  RedOak's solution is based on the Saffron Natural Intelligence Platform, the world's first commercial, scalable associative memory technology for sense-making, decision support and predictive analytics.  

"Let's face it: The current drug development model is broken. The amount of information drug companies must manage is unfathomable; they can't make sense of it all.  Current decision support and data analytics tools are inadequate.  As a result, the international drug development industry is underperforming.  RedOak Logic has been formed to deliver a Saffron-based Experience Management solution to redefine the way drug manufacturers bring products to market, so they can produce more effective drugs faster and more profitably," said Dale Fedewa, founder and CEO, RedOak Logic.  

Using RedOak's pharmaceutical industry solution, drug development companies will be able to capture and utilize all types of data -- public and proprietary, structured and unstructured  -- giving them unlimited capacity to make fully supported decisions on critical issues, such as:

  • Avoiding investments of time and resources in pursuit of ultimately unsuccessful drug candidates
  • Attaining meaningful and perceptive appreciation of safety, dosage and efficacy data
  • Detecting and outmaneuvering disease variables in study concept and execution
  • Quantifying, controlling, and capitalizing on the "human element" in the design and conduct of clinical trials
  • Maximizing operational efficiencies in drug delivery
  • Accelerating regulatory approval, market introduction, and market penetration.

  • "The pharmaceutical industry sails in turbulent, uncertain seas and urgently needs more effective ways to successfully navigate the increasingly complex maze of product development," said W. Neal Burnette, chief scientist, RedOak Logic Advisory Board.  "The sextant of this journey is one that can acquire all the information and data, filter it for relevancy, and plug it into a decision matrix to direct the path of drug development and enable real-time course corrections.  RedOak Logic is that sextant."

    AvailabilityRedOak's standard, base platform will reside on the cloud and the application interface will be customized to fit the business needs and culture of each company. Use-based pricing is anticipated. RedOak is currently working with Beta customers. Product availability is estimated for 2011.  For more information, contact Dale Fedewa, CEO (  

    About RedOak LogicRedOak Logic LLC is applying the Saffron Natural Intelligence Platform to help the $800 billion global pharmaceutical industry bring safer, more effective drugs to market faster and at lower cost.  The company's Advanced Decision Model Support platform will enable pharmaceutical companies to accelerate the clinical trials process, where "too much information" often impedes a company's operational efficiency.  By better utilizing the collective Experience hidden in business-critical public and private data, RedOak's solutions, built on Saffron 8, will enable better sense-making, decision support and predictive analytics, speeding decisions and improving time to market.  For more information about RedOak, email Dale Fedewa, CEO, at

    RedOak Logic.  Enabling Intelligence in Drug Development

    About The Saffron Natural Intelligence Platform Built on associative memory technology, Saffron is the new framework for Experience Management, the Business Intelligence of the future. Semantically connected, statistically rich with frequencies, free of traditionally bounded models of statistics and rules, and powered by service-oriented technology architecture, Saffron continuously identifies patterns and situations and creates memories of what's in the data.  As new data arrives, new memories are formed, so the "Experience" in your data can be captured and applied.  The Saffron Natural Intelligence Platform learns incrementally about connections and frequencies among people, places, things and events. The result is a multi-dimensional, non-parametric, massively scalable, connection engine capable of helping enterprises achieve new breakthroughs in real-time analysis, business intelligence and national security.

    About Saffron Technology Saffron helps business and IT leaders apply the collective Experience hidden in their data to better understand situational scenarios, determine best possible courses of action, and make higher value decisions about mission-critical issues.  Saffron's customers in academia, corporations and government are engaged in high-stakes research, financial services, risk management, supply chain operations, national security, health care, social media & marketing, and more.  SaffronSierra ( is a Platform-as-a-Service (PaaS) for developers creating new applications with the Saffron Natural Intelligence Platform, including SaffronMemoryBase™.  To learn more, visit

    Saffron Technology. The World of Experience.™MEDIA CONTACT:John SawyerThe Anvil-Chinook Agency

    SOURCE RedOak Logic LLC
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
    2. New FDLI Monograph Provides Expert Guidance on Selling Pharmaceuticals, Biologics to Federal Government
    3. Circle Biologics® Introduces Innovation in Medical Devices
    4. Pioneer® Surgical Expands Product Specialists to Support Growing Biologics Business
    5. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
    6. Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
    7. Clive Dix Appointed as Chairman of Crescendo Biologics
    8. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
    9. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
    10. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
    11. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
    Post Your Comments:
    (Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, ... it has completed the acquisition of Kremers Urban ... subsidiary of global biopharmaceuticals company UCB S.A. (Euronext: ... Lannett has acquired KU from UCB for ... certain adjustments, including a customary working capital adjustment, ...
    (Date:11/26/2015)... 2015 Un nuevo enfoque combina ... el cáncer avanzado.   --> Un ... de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... --> Clinical Cancer Research . --> ...
    (Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
    Breaking Medicine Technology:
    (Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
    (Date:11/27/2015)... ... November 27, 2015 , ... ... Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into its ... 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will ...
    (Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also think ... during the Black Friday and Cyber Monday massage chair sales to receive ... high and low to find the best massage chair deals, they can see all ...
    (Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today ... owner, Somu now offers travelers, value and care based Travel Services, including exclusive ... as well as, cabin upgrades and special amenities such as, shore excursions, discounted ...
    (Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the many ... Medical Group . These fields, as well as travel nursing, ranked at ... through the company’s website, , The leading healthcare staffing agency released ...
    Breaking Medicine News(10 mins):